Aerie Pharmaceuticals Inc ((AERI)) announced an update on their ongoing clinical study.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Study Overview: Aerie Pharmaceuticals Inc. recently completed a Phase 3 study titled ‘COMET-2’ to evaluate the safety and efficacy of AR-15512, a cold thermoreceptor modulator, for treating dry eye disease. This study is significant as it aims to provide a new treatment option for patients suffering from this common condition.
Intervention/Treatment: The study tested the AR-15512 ophthalmic solution, administered as one drop in each eye twice daily, against a placebo vehicle. The goal was to assess its effectiveness in improving symptoms of dry eye disease.
Study Design: The study was interventional, randomized, and double-masked, meaning neither participants nor investigators knew who received the actual treatment. It followed a parallel assignment model with a primary purpose of treatment, ensuring a robust evaluation of AR-15512’s effectiveness.
Study Timeline: The study began on May 9, 2022, and was completed on July 22, 2025. These dates are crucial for understanding the study’s duration and the timeline for data analysis and reporting.
Market Implications: The completion of this study could positively impact Aerie Pharmaceuticals, now part of Alcon, by potentially enhancing its product portfolio with a new treatment for dry eye disease. Positive results might boost investor confidence and influence stock performance, especially in a competitive market where effective treatments are in demand.
The study is completed, and further details are available on the ClinicalTrials portal.